Navigation Links
Clinical Outcomes of Nonsmall Cell Lung Cancer Patients can Be Classified by New Algorithms

Two research teams have developed models for classifying the clinical outcomes of patients with nonsmall-cell lung cancer (NSCLC) using mass spectrometry techniques . Currently, clinicians do not have adequate methods for determining which patients will benefit from treatment with certain drugs. The new models could help physicians decide who will benefit from certain treatment options.

The studies are published in the June 6 Journal of the National Cancer Institute. In one study, an international team led by David Carbone, M.D., Ph.D., of the Vanderbilt-Ingram Cancer Center in Nashville, developed an algorithm to predict the outcomes of NSCLC patients treated with the drugs gefitinib and erlotinib, two tyrosine kinase inhibitors. The algorithm places patients into categories indicating good or poor survival before treatment with one of the drugs and is based on the pattern of a group of proteins in the patients blood serum.

The authors developed the algorithm on a group of patients with known outcomes then tested it on pretreatment serum for independent validation and control groups. Patients who were predicted to have good outcomes survived for a median of 306 days, while those in the poor group survived a median of 107 days.

In the clinical development of biomarkers for the individualization of therapy, it is important to distinguish between those who will benefit from an intervention from those independent of the planned intervention. Biomarkers predictive for survival benefit from an intervention are much more useful for guiding managementthe authors said.Use of (Protein)signature will reduce rates of both overtreatment and undertreatment and improve survival for NSCLC patients, the authors added.

In the second study, Kiyoshi Yanagisawa, M.D., Ph.D., of Nagoya University in Japan, and colleagues analyzed protein patterns in NSCLC tumor tissue and normal lung tissue. The researchers identified a pattern th at was associated with increased survival among NSCLC patients and may distinguish patients with poor prognosis from those with good prognosis. They also tested their model on independent validation and control groups.


'"/>




Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Renal Trails Do Not Have Sufficient Women Participants
7. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
8. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
9. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
10. Cancer Clinical Research in India
11. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... Monica, CA (PRWEB) , ... May 03, 2016 , ... ... the highest quality medical providers to build the leading network of doctors and therapists ... Eric Nepomnaschy, D.C., founder of the distinguished Bay Chiropractic and Rehabilitation in ...
(Date:5/3/2016)... ... May 03, 2016 , ... SELEX (systematic evolution ... from a random library of sequences depending on their attraction for a target ... SELEX selection is commonly performed using filters, panning, or affinity chromatography separations. However, ...
(Date:5/3/2016)... FL (PRWEB) , ... May 03, 2016 , ... ... leading innovative specialty pharmacies, will be represented at the 2016 Asembia Specialty ... Vegas. The Asembia Summit is the largest U.S. health care conference for the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its ... situations or practice tricky or rare procedures in an environment that looks and feels ... is also available to inventors and “hackers” to develop and test new devices or ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announces Benefits Alliance Insurance Services as the latest addition to its elite stable ... comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The Firm is ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... 29, 2016 Glycotope GmbH, a ... announces the appointment of Dr. Alfredo Zurlo ... an oncologist with many years clinical experience and a ... His last role was at Mologen AG where he ... Board. Previously Dr. Zurlo held various positions at F ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
Breaking Medicine Technology: